Novo Nordisk built modern obesity pharmacology. Liraglutide came first in 2009, with Saxenda following in 2014. Semaglutide split into three products — Ozempic for type-2 diabetes, Wegovy for obesity, and Rybelsus as the oral form. The 2025 and 2026 cadence has been about defending that position against Lilly's tirzepatide while moving the next generation forward.
The May 6 Q1 2026 print landed strong: net sales DKK 96.82B (+24% YoY), operating profit DKK 59.62B (+54%). Wegovy pill drove the upside with DKK 2.26B (~$354M) in Q1 — almost 2× analyst consensus — on roughly 1.3 million Q1 prescriptions and 2 million-plus cumulative since the January 5 launch. CEO Mike Doustdar told CNBC on May 6 that Wegovy holds 65% of all new US GLP-1 prescriptions, calling the moment a 'turnaround situation.' NovoCare priced the 1.5 mg starter at $149/month and moved the 4 mg dose from $149 to $199 effective April 15. On May 1, Novo officially retired the Rybelsus US brand and re-launched the same molecule as Ozempic Pill at 1.5/4/9 mg with improved-absorption reformulation across 70,000+ pharmacies. Wegovy HD 7.2 mg launched April 7 with a STEP UP 21% mean weight loss anchor. Full-year guidance tightened to a 4–12% sales-and-operating-profit decline (from the prior 5–13%) — Jefferies pushed back that the lower-end guidance was not lifted enough to be a positive surprise.
The pipeline gets harder from here. CagriSema (cagrilintide + semaglutide) failed to match Zepbound in February's head-to-head readout (23% vs 25.5%), and the Q1 documents disclosed Novo has discontinued the single-chamber co-formulation device — the dual-chamber injectable system continues with the original FDA filing already submitted and a higher-dose Phase 3 trial slated for H2 2026. Petrelintide and amycretin-prodrug sit further back. The Indian semaglutide patent expired in March 2026 and licensed generics from Biocon and Dr. Reddy's followed within weeks.
International milestones continued through Q2 2026. Japan's MHLW granted Novo Nordisk a partial change approval on June 19, 2026 making Wegovy the first approved MASH treatment in Japan (without cirrhosis, moderate-to-advanced fibrosis), co-promoted with Sumitomo Pharma under the October 2025 co-promotion agreement and based on ESSENCE Phase 3 Part 1 data. France joined the UK and Switzerland with public-insurance reimbursement effective June 15, 2026 at 65% Sécurité Sociale coverage, and the UAE became the first ex-US Wegovy pill launch on June 3.
September 7, 2026 was a split-decision day. STEP Young reported that 40.4% of children aged 6 to under 12 with obesity achieved a BMI below the obesity threshold at week 68 on semaglutide plus lifestyle modification, versus 0% on placebo, with safety consistent with adult and adolescent trials and no signal on growth or pubertal development — potentially opening a supplemental filing path to extend Wegovy below its current 12-and-older label. On the same day the company confirmed it had terminated the HERMES and ATHENA Phase 3 heart failure trials of ziltivekimab (anti-IL-6 monoclonal antibody) early after a data monitoring committee ruled the studies unlikely to succeed, following the June 2026 ZEUS miss. A post-acute heart-failure study of ziltivekimab remains ongoing, but the non-GLP-1 diversification story has narrowed further.
Analyst sentiment split further into the week of September 8-11. HSBC raised its Novo Nordisk target to DKK 320 from DKK 300 (Hold, September 9) after early-week positive newsflow, and Barclays cut its target from DKK 310 to DKK 300 (Equal Weight, September 8) after the STEP Young + ziltivekimab split announcement. Morgan Stanley's Thibault Boutherin then downgraded Novo to Underweight from Equal-weight on Friday September 11, cutting the price target to DKK 250 (implying more than 10% downside) on concerns that current valuation does not reflect the subdued mid-term growth outlook or the semaglutide patent-cliff impact on Novo's terminal value. Morgan Stanley flagged that semaglutide is expected to account for approximately 75% of 2026 sales, with loss of exclusivity beginning in 2031, and cited weaker U.S. Wegovy pill script momentum after a stronger first half. Novo shares closed the week down 2.8% in Copenhagen at DKK 278.2 and 3.1% in Frankfurt at EUR 36.89. The company continued executing the DKK 15 billion share repurchase programme (DKK 9.02 billion completed through September 4).
On Monday September 14, 2026 the company said it would use 'Novo' as its day-to-day name, while Novo Nordisk A/S remains its legal name. The rebrand introduced the platform 'Lasting Health Starts Now,' an updated version of the Apis bull logo, and a culture framework called The Novo Way, and the company said it would give more detail on its strategy at a Capital Markets Day in London on September 21. On Wednesday September 16, Novo and Anthropic announced a collaboration under which Novo will test Anthropic's Claude Science in research and development workflows; financial terms were not disclosed. On Thursday September 17, Novo signed a multi-target discovery and license agreement with Orbis Medicines, a Copenhagen and Lausanne company that designs oral macrocycle drugs, worth up to $1.4 billion in upfront and milestone payments plus tiered royalties, along with a strategic investment of undisclosed size. Orbis's chief executive said its macrocycles have reached up to 18% oral bioavailability in preclinical studies.
Novo set out its 2030 ambitions at the Capital Markets Day in London on Monday September 21, 2026: launch more than five multi-blockbusters, run at least five Phase 3 programs in obesity and diabetes and at least five in other therapy areas, serve more than 60 million patients, build capacity to serve 10 times more people with obesity on oral GLP-1, keep a broadly stable operating margin, and grow revenue from 2026 to 2030 in line with industry peers. It also targets more than DKK 150 billion (about $23 billion) in pipeline sales in 2035 and said the ambitions are not financial guidance. Management said CagriSema would launch early next year, followed by standalone cagrilintide and high-dose CagriSema in 2028, with zenagamtide planned in oral and injectable forms. Shares fell as much as 9% during the day, BNN Bloomberg reported, as management faced questions on pricing and dealmaking.
At the Aging Research and Drug Discovery (ARDD) meeting at Harvard on October 1-3, 2026, Novo Nordisk researchers reported that in protein data from 10,052 participants in five semaglutide trials, the drug lowered an estimate of heart biological age by about 2 to 4 years at the first follow-up measurement, according to the meeting's poster abstracts. Longevity.Technology reported on October 4 that Novo also modeled SELECT trial results in a UK cohort of 19,117 people to project 1.9 life-years gained, and that a Lilly epigenetic substudy with 71 paired SURMOUNT-5 participants found all 15 epigenetic clocks showed less aging than the 1.38 years that had passed, two of them statistically significant. Lilly called its work preliminary and hypothesis-generating, with no placebo or control group, and biological-age clocks are not established clinical outcomes.
Novo Nordisk reported on Thursday, October 1, 2026, at EASD in Milan, a post hoc, exploratory analysis pooling 1,919 adults from its STEP UP and STEP UP T2D trials who took Wegovy 7.2 mg, Wegovy 2.4 mg, or placebo. In a 55-person subgroup whose liver fat was measured by MRI, average liver fat fell from 8.8% at baseline to 3.1% at week 72, and 23 of the 26 participants who started above the 5% threshold for fatty liver ended below it. Liver fat was not a prespecified endpoint of either trial, and Novo pooled the two Wegovy doses for the MRI result.
Novo Nordisk said on Friday, October 2, 2026 that the FDA's review of its biologics license application for denecimig, a bispecific antibody that mimics activated clotting factor VIII in hemophilia A, is still ongoing with no new action date because of remediation work at a manufacturing facility. Novo filed in September 2025 and had expected a decision in the third quarter of 2026; the FDA has not identified deficiencies in the clinical efficacy or safety data, and Novo now aims to launch in the U.S. in the first half of 2027. The company said the delay does not change its 2026 financial outlook.
Full results of Novo's REMODEL trial, first presented at the 2026 World Congress of Nephrology, were published in Nature Medicine on Thursday, October 1, 2026. The trial randomized 106 adults with type 2 diabetes and chronic kidney disease to semaglutide 1 mg weekly or placebo for 52 weeks to learn how the drug protects the kidneys. Its coprimary MRI measures of kidney oxygenation, perfusion, and inflammation did not change significantly versus placebo, but semaglutide lowered the renal artery resistive index and kept stable an MRI marker the authors link to scarring, and paired biopsies showed marked effects on the cells lining the kidney's filtering blood vessels, with fewer immune cells nearby. Urine albumin fell 40% in an exploratory analysis; Novo Nordisk funded the trial.
Novo presented at EASD on Wednesday, September 30, 2026 OCTANE, a retrospective analysis of de-identified data from the telehealth company Ro covering 194 adults who switched from injectable semaglutide or tirzepatide to the once-daily Wegovy pill between January 5 and February 7, 2026. From a mean baseline weight of 100.5 kg and BMI of 34.5, participants lost an average of 4.1% of body weight (4.0 kg) over three months, 40.7% lost at least 5%, and the share with a BMI of 30 or higher fell from 87.1% to 65.5%. Novo listed limitations including self-reported and incomplete data and selection bias from counting only people who stayed on treatment; the release did not give the injectable doses people switched from.
Novo and Jiangsu Hengrui Pharmaceuticals announced on Tuesday, September 29, 2026 an exclusive license giving Novo global rights to HRS-1596, a GLP-1/GIP dual receptor agonist being developed for once-weekly oral dosing, outside mainland China, Hong Kong, Macao, and Taiwan, where Hengrui keeps the rights. Novo will pay $300 million upfront, and the deal is worth up to $2.6 billion including development, regulatory, and commercial milestones, plus royalties on sales. HRS-1596 is described as Phase 1-ready for weight management and type 2 diabetes; the deal requires Hart-Scott-Rodino clearance and is expected to close in the fourth quarter of 2026. Novo R&D chief Martin Holst Lange said the company wants to explore whether the drug can 'raise the bar for convenience.'
Swedish drug-delivery company Nanexa announced on the evening of Thursday, September 24, 2026 a global exclusive license and collaboration agreement giving Novo Nordisk rights to use its PharmaShell platform in up to five development programs for peptide-based drugs in obesity, type 2 diabetes, and other cardiometabolic diseases. PharmaShell uses atomic layer deposition to apply an ultra-thin inorganic coating to individual drug particles to control their release, and the companies are targeting monthly and quarterly injection schedules. Nanexa can receive up to €1.165 billion, of which €615 million is an upfront payment plus development and regulatory milestones and the rest is sales milestones, along with low single-digit royalties; Novo will lead development and commercialization. Reuters reported that Nanexa's shares were up about 122% in Stockholm early on Friday, September 25.
Novo Nordisk shares fell about 8% in both Copenhagen and New York on Monday, September 21, 2026, the day of its London Capital Markets Day, according to GEN. BMO Capital Markets analyst Evan Seigerman wrote that Novo is "targeting 2026-2030 revenue growth in line with industry peers, likely underwhelming for investors," and noted that consensus already models about 3.53% annual growth for Novo against roughly 3.65% for pharma peers, so the target appeared priced into Wall Street estimates. The company used the event to set 2030 ambitions that included more than five potential blockbuster launches.
Novo Nordisk set out its 2030 ambitions at its Capital Markets Day in London on Monday, September 21, 2026: launch more than five multi-blockbusters, run at least five Phase 3 programs in obesity and diabetes and at least five in other therapy areas, serve more than 60 million patients, build capacity to serve 10 times more people with obesity on oral GLP-1, keep a broadly stable operating margin, and deliver 2026-2030 revenue growth in line with industry peers. It also targets more than DKK 150 billion (about $23 billion) in pipeline sales in 2035, and it said the ambitions are not financial guidance. Shares fell as much as 9% and were down 4.7% by 11:24 GMT, BNN Bloomberg reported, as management faced questions on pricing and dealmaking. Management said CagriSema would launch early next year, followed by standalone cagrilintide and high-dose CagriSema in 2028, with zenagamtide planned to launch in oral and injectable forms at the same time; BNN Bloomberg also reported a plan to scale manufacturing tenfold to supply 15 million patients with oral obesity therapies by the end of the decade.
Novo Nordisk announced on Thursday, September 17, 2026 that the EMA's CHMP recommended marketing authorization for FREHEMGO (denecimig) to treat hemophilia A, with or without inhibitors, in adults and children. Denecimig is a factor VIIIa-mimetic bispecific antibody that bridges factor IXa and factor X to mimic the cofactor function of activated factor VIII. Novo says it is the first FVIIIa mimetic to offer once-monthly, once-every-two-weeks, and once-weekly prophylaxis in a single-use pre-filled pen. The application was based on the FRONTIER2, FRONTIER3, and FRONTIER4 trials, and FRONTIER5 showed no new safety signals in patients switching from emicizumab. Pending a European Commission decision, Novo expects launches in the first European countries in Q4 2026 and across the EU starting early 2027.
Orbis Medicines, based in Copenhagen and Lausanne, announced on Thursday, September 17, 2026 a multi-target discovery and license agreement with Novo to design oral macrocycle drugs for undisclosed cardiometabolic targets. Orbis can receive up to $1.4 billion in upfront and development and commercial milestone payments plus tiered royalties, and Novo will make a strategic investment of undisclosed size. The work uses Orbis's nGen platform, which combines generative AI, high-throughput synthesis, and a multi-parameter optimization engine trained on the company's experimental macrocycle data. Orbis chief executive Morten Graugaard said its synthetic macrocycles have reached up to 18% oral bioavailability in preclinical studies. Orbis launched in January 2025 with a €90 million (about $93 million) Series A led by NEA, with Lilly Ventures, Forbion, and Novo Holdings among its investors.
Novo will hold its Capital Markets Day in London on Monday, September 21, 2026, with CEO Mike Doustdar presenting the corporate strategy. A TIKR preview published September 10 noted that the U.S.-listed shares closed at $44.56 on September 9, nearer their 12-month low of $35.12 than their high of $64.16. The preview put total Wegovy pill prescriptions past five million, with the latest million added in four weeks, and the pill's share of the U.S. oral obesity market at about 90%. It also pointed to a U.S. obesity decision on CagriSema at the end of 2026 and to semaglutide losing exclusivity in markets such as Canada and Brazil in the second half of 2026. The event follows Novo's announcement that it will drop 'Nordisk' from its name in day-to-day use.
Novo Nordisk announced on Monday, September 14, 2026 that it will use 'Novo' as its day-to-day company name, while Novo Nordisk A/S remains its legal name. The rebrand introduces the platform 'Lasting Health Starts Now,' an updated version of the Apis bull logo, and a culture framework called The Novo Way, built on customer obsession, competitiveness, clarity, and care and integrity. CEO Mike Doustdar said healthcare "must become more responsive, relevant and easier to fit into everyday life." The company said it would present more detail on its strategy at its Capital Markets Day in London on September 21, 2026.
Novo Nordisk and Anthropic announced on Wednesday, September 16, 2026 a collaboration under which Novo Nordisk will test Anthropic's Claude Science in specific research and development workflows and use Anthropic's frontier models for biological reasoning, drug discovery, and AI-driven software development. Financial terms were not disclosed. Novo Nordisk CEO Mike Doustdar said AI can help the company increase R&D productivity and "compress the path from research to marketed product." Anthropic co-founder and CEO Dario Amodei said giving researchers access to frontier models can shorten research timelines.
Novo Nordisk said on Wednesday, September 16, 2026 that it will present 44 abstracts at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, from September 28 to October 2. The OCTANE study will report real-world data on Wegovy pill use, including weight outcomes, treatment switching, and patient-reported outcomes. Other presentations cover Wegovy 7.2 mg; CagriSema (cagrilintide plus semaglutide) data on appetite regulation, eating behavior, body composition, and bone remodeling from the REDEFINE and REIMAGINE programs; and zenagamtide, the unimolecular GLP-1 and amylin receptor agonist formerly called amycretin.
STAT News published Tuesday September 15, 2026 a landscape piece flagging that obesity drug developers have expanded pediatric trial testing to include children as young as six years old, extending the age range down from the Wegovy 12-and-older U.S. label. Novo Nordisk's STEP Young Phase 3 (topline reported September 7) tested once-weekly semaglutide in 165 children aged 6 to under 12 with obesity: 40.4% of the semaglutide group achieved a BMI below the obesity threshold at week 68 versus 0% on placebo, with no new safety concerns and no signals for growth or pubertal development. STAT flagged additional pediatric-obesity trial activity following the January 2023 AAP Clinical Practice Guideline endorsement of medication therapy for children aged 12+ and consideration in ages 6-11. The September 4 Pediatrics journal publication documented a 310-fold increase in GLP-1 prescribing to U.S. children aged 8-11 with obesity between 2019 and mid-2026 (0.03% to 9.3%), with 93.7% of recipients having severe obesity and 65.2% having weight-related comorbidities. Full STEP Young results are scheduled for ObesityWeek 2026 (November 14-17, Washington DC). No Wegovy sNDA for ages under 12 has been filed as of September 15, 2026.
Novo Nordisk (NYSE: NVO; Copenhagen: NOVO-B) heads into the week of September 14-19, 2026 with the September 21 Capital Markets Day in London one week away, and Friday September 11 fresh in investor minds. Morgan Stanley analyst Thibault Boutherin had cut Novo Nordisk to Underweight from Equal-weight Friday with a DKK 250 price target (implying more than 10% downside) citing subdued mid-term growth outlook plus concerns about the semaglutide loss-of-exclusivity beginning 2031 (semaglutide accounts for approximately 75% of Novo's 2026 sales). HSBC on Wednesday September 9 had raised its price target to DKK 320 (Hold), and Barclays on September 8 had trimmed its target to DKK 300 (Equal Weight). Novo shares closed the prior week down 2.8% in Copenhagen at DKK 278.2. The London Capital Markets Day is expected to unveil fresh strategic ambitions to replace existing targets, plus pipeline detail on CagriSema (cagrilintide + semaglutide) after the February 2026 Redefine-1 head-to-head miss versus Zepbound (23% vs 25.5% weight loss), amycretin (GLP-1/amylin unimolecular dual agonist Phase 3 planning), and the post-semaglutide non-GLP-1 diversification story after the September 7 HERMES + ATHENA ziltivekimab heart-failure trial terminations.
Morgan Stanley analyst Thibault Boutherin and team cut Novo Nordisk (NYSE: NVO; Copenhagen: NOVO-B) to Underweight from Equal-weight on Friday September 11, 2026, with a DKK 250 price target implying more than 10% downside from current levels. The downgrade thesis: Novo's current valuation does not fully reflect the subdued mid-term growth outlook or the semaglutide patent-cliff implications on the company's terminal value. Semaglutide is expected to account for approximately 75% of Novo's 2026 sales; loss of exclusivity begins in 2031 across major markets. Morgan Stanley also flagged weaker momentum in U.S. Wegovy pill prescriptions following a stronger first half of 2026. Novo shares closed the week down 2.8% in Copenhagen at DKK 278.2 and 3.1% in Frankfurt at EUR 36.89. HSBC on Wednesday September 9 had raised its price target to DKK 320 (from DKK 300) while maintaining a Hold rating, framing the analyst split. Barclays cut its price target to DKK 300 from DKK 310 September 8 following the STEP Young + ziltivekimab HERMES/ATHENA split announcement, and Guggenheim earlier moved its target on Roivant/Pulmovant PHocus success. Novo executed DKK 9.02 billion of the DKK 15 billion share repurchase through September 4.